Encapsulated human mesenchymal stem cells: a unique hypoimmunogenic platform for long-term cellular therapy

Area of Science:

• Biotechnology
• Regenerative Medicine
• Immunology

Background:

• Cell encapsulation offers potential for long-term therapeutic agent delivery but faces challenges due to host immune reactions.
• Mesenchymal stem cells (MSCs) are hypoimmunogenic and can be genetically modified, presenting a promising solution for cell-based microencapsulation therapies.

Purpose of the Study:

• To develop and evaluate alginate-PLL microcapsules for encapsulating human MSCs (hMSCs) for therapeutic applications.
• To assess the immunogenicity and efficacy of encapsulated hMSCs in a glioblastoma tumor model.

Main Methods:

• Human MSCs were encapsulated in alginate-PLL microcapsules, and their viability, surface markers, and differentiation potential were assessed.
• In vitro and in vivo immunogenicity studies were performed, comparing encapsulated hMSCs to other cell lines.
• hMSCs were genetically modified to express the hemopexin-like protein (PEX) and encapsulated for anti-angiogenesis therapy.

Main Results:

• Encapsulated hMSCs remained viable, maintained mesenchymal markers, and differentiated into mesodermal lineages.
• Encapsulated hMSCs exhibited significantly reduced immunogenicity, with a 3-fold decrease in cytokine expression compared to entrapped cell lines.
• Encapsulated hMSC-PEX significantly reduced glioblastoma tumor volume (87%) and weight (83%) in nude mice.

Conclusions:

• Human MSCs are a suitable cell type for microencapsulation-based cell therapy due to their hypoimmunogenicity and therapeutic potential.
• Microencapsulated hMSCs demonstrate reduced immunogenicity and significant efficacy in reducing glioblastoma tumor growth.
• This technology advances cell-based therapies towards clinical application.